GlassScriptPhysician profile
William Arch Welton
NPI 1043204365
$2,842.13
in general payments reported to CMS, 2019-2025
23 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 76% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.18 · 2020: $44.02 · 2021: $167 · 2022: $378 · 2023: $525 · 2024: $567 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $416.52 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $384.91 | 2022-2025 | Sotyktu |
| Abbvie INC. | $327.54 | 2022-2025 | Skyrizi |
| Leo Pharma INC. | $285.47 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $230.88 | 2023-2025 | Odomzo, Blu-U, Ilumya |
| Ucb, INC. | $216.05 | 2024-2025 | Bimzelx |
| Smith+Nephew, INC. | $186.17 | 2020-2023 | Grafix Pl |
| Kerecis Limited | $168.69 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $160.97 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $69.68 | 2022-2024 | Ebglyss |
| Genzyme Corporation | $65.22 | 2022-2024 | |
| Organogenesis INC. | $47.56 | 2021-2023 | Puraply |
| Pfizer INC. | $43.70 | 2022-2023 | |
| Galderma Laboratories, L.P. | $38.87 | 2019-2021 | |
| Sensus Healthcare, INC. | $38.68 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.90 | 2024 | Siliq, Duobrii |
| Hill Dermaceuticals, INC. | $23.98 | 2023 | Tolak |
| Novartis Pharmaceuticals Corporation | $21.87 | 2024 | |
| Organon LLC | $21.00 | 2025 | Vtama |
| Paratek Pharmaceuticals, INC. | $20.59 | 2022 | |
| Dermavant Sciences, INC. | $20.06 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $17.17 | 2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Welton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.